The purity of the peptides was >95%. MBP Ac1–9 analog peptides were administered i.n. at 100 μg of peptide in 25 μL of
PBS under light either halothane or isoflurane anesthesia at 3–4 day intervals over a period of 5 wk. Mice MAPK Inhibitor Library clinical trial used for experiments were treated with 10 to 14 doses of MBP Ac1–9 peptides. EAE was induced in mice on day 0 by s.c. injection of 1 mg spinal cord homogenate (SCH) or 50 μg of MBP Ac1-25[4K] in 0.1 mL of emulsion consisting of equal volumes of PBS and CFA (BD Biosciences) containing heat-killed Mycobacterium tuberculosis (BD Biosciences) at 4 mg/mL. Pertussis toxin (PT) (200 ng) (Sigma-Aldrich) was administered by i.p. injection in 0.5 mL of PBS on days 0 and 2. Mice were monitored for disease for 40 days post-immunization. Clinical signs of EAE were assessed daily with a 0 to 5 scoring system as follows: 0, no disease; 1, flaccid tail; 2, impaired righting reflex and/or partial hind leg paralysis; 3, total hind limb paralysis; 4, fore and hind limb paralysis; 5, moribund or dead. Splenocytes from naïve Tg4 mice were CP-673451 solubility dmso labeled with 5-(and-6)-carboxyfluorescein diacetate succinimidyl ester as described
previously 30 and suspended in PBS at 1×108 cells/mL. On day 0, 0.5 mL of the cell suspension was transferred to untreated or 10× MBP Ac1–9[4K]-, [4A]- or [4Y]-treated recipient Tg4 mice i.p. Mice received a challenge of one i.n. dose of PBS or MBP Ac1–9 peptides on day 1 after transfer. On day 3, the spleens from the recipient mice were harvested, cells stained with anti-CD4 APC, anti-CD69 PE and PI (BD Biosciences), and the CD4+ T-cell proliferation/activation, as measured by CFSE dilution/CD69 expression, determined by flow cytometry. The division index, the average number of times that each responding cell has divided, was calculated Etomidate using FlowJo (Tree Star) FACS analysis software. Purified CD4+ T cells were isolated from spleens by magnetic separation using mouse CD4 (L3T4) MicroBeads (Miltenyi Biotec) according to the manufacturer’s instructions. CD4+ T cells were cultured at 5×104per well in complete RPMI medium (RPMI-1640
medium (Cambrex Bio Science) supplemented with 20 mM Hepes Buffer, 50 mM 2-Mercaptoethanol (Sigma-Aldrich), 100 U/mL penicillin and 100 μg/mL streptomycin sulfate, 4 mM L-Glutamine (Cambrex Bio Science) and 5% heat-inactivated fetal bovine serum (Sigma-Aldrich)) in round-bottomed 96-well plates at 37°C and 5% CO2 humidified atmosphere in the presence of 1×105 irradiated B10.PL splenocytes as APC. MBP Ac1–9[4K], [4A] or [4Y] ranging from 0.01 to 100 μg/mL were added to the cultures where indicated. Prior to in vitro suppression assays, splenocytes from i.n. peptide-treated mice were routinely expanded in vitro in the presence of recombinant human (rhIL-2) (R&D Systems) as follows. Spleens were isolated 3 days after the last i.n. peptide treatment and disaggregated to form single cell suspension and re-suspended at 1.